OBJECTIVES Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infection as a preemptive treatment after liver transplantation. METHODS Between 2012 and 2...

In a prospective study of solid-organ transplant recipients (n = 22; 15 hepatic and 7 renal) receiving valganciclovir for cytomegalovirus (CMV) prophylaxis, electronic estimation of glomerular filtration rate (eGFR) underestimated the true GFR (24-h urine creatinine clearance) by >20% in 14/22 (63.6%). Its use was associated with inappropriate underdosing of valganciclovir, while the Cockroft-G...

background: cytomegalovirus (cmv), a problematic virus in solid organ transplant recipients (sotr) such as liver, can worsen overall mortality and transplant outcome, so its prevention and treatment is a key of success in such patients. this study is aimed to compare the efficacy of ganciclovir (gcv) and valganciclovir (vgc) for prevention and treatment of infection with cmv. materials and meth...

PURPOSE To describe 7 cases of unilateral, chronic and/or recurrent anterior uveitis caused by cytomegalovirus (CMV) in immunocompetent patients; to identify specific ophthalmologic characteristics; and to evaluate the clinical effect of valganciclovir treatment. DESIGN Retrospective observational case series. PARTICIPANTS Immunocompetent patients (n = 7) with a history of chronic and/or re...

The risk of late-onset cytomegalovirus (CMV) infection remains a concern in seronegative kidney and/or pancreas transplant recipients of seropositive organs despite the use of antiviral prophylaxis. The optimal duration of prophylaxis is unknown. We studied the cost effectiveness of 6- versus 3-mo prophylaxis with valganciclovir. A total of 222 seronegative recipients of seropositive kidney and...

BACKGROUND Valacyclovir has been used for prophylaxis against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT). We investigated the efficacy and safety of high-dose Valacyclovir as pre-emptive therapy in patients with CMV antigenemia after HSCT. METHODS In a retrospective single center study of 61 patients, we compared the rates of viral clearance, recurren...

Efforts to prevent relapsed cytomegalovirus (CMV) disease among solid organ transplant (SOT) recipients present clinical challenges. Historically, SOT recipients treated with short courses of ganciclovir, without documented clearance of viremia, had relapse rates of 23-33%. Current treatment often includes much longer courses of valganciclovir, and persistence of viremia at the end of treatment...

PURPOSE We evaluated the efficacy and safety of the current cytomegalovirus (CMV) prophylaxis regimen used at Virginia Mason Medical Center in Seattle. METHODS A single-center, retrospective analysis was conducted in a regional renal transplantation center at a tertiary teaching facility. STUDY POPULATION Seventy patients who underwent kidney and/or pancreas transplantation from October 200...

BACKGROUND The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for treatment of CMV disease in solid organ transplant (SOT) recipients. METHODS Viral genes (UL97 and UL54) conferring ganciclovir resistance were amplified and sequenced from blood samples collected at days 0 (before thera...